Xianju Pharmaceutical (002332.SZ): Progesterone vaginal tablets received US FDA registration application accepted

Zhitong Finance App News, Xianju Pharmaceutical (002332.SZ) issued an announcement. The company submitted an ANDA registration application for progesterone vaginal tablets to the US Food and Drug Administration (“FDA”). The company recently received a notice of acceptance of the US FDA registration application. The indication for progesterone vaginal tablets is ART luteal support for assisted reproduction. By supplementing luteal function, it supports embryo implantation and early pregnancy.